Participation of tumour necrosis factor and nitric oxide in the mediation of vascular dysfunction in splanchnic artery occlusion shock - PubMed (original) (raw)
Participation of tumour necrosis factor and nitric oxide in the mediation of vascular dysfunction in splanchnic artery occlusion shock
F Squadrito et al. Br J Pharmacol. 1994 Dec.
Abstract
1. Splanchnic artery occlusion (SAO) shock is characterized by irreversible circulatory failure. Tumour necrosis factor (TNF-alpha) may affect the L-arginine/nitric oxide (NO) pathway, thus contributing to the cardiovascular derangements of circulatory shock. 2. We investigated the contribution of both TNF-alpha and the L-arginine/nitric oxide pathway to the vascular dysfunction of SAO shock. Anaesthetized rats, subjected to total occlusion of the superior mesenteric artery and the coeliac trunk for 45 min developed a severe shock state (SAO shock) resulting in a fatal outcome within 75-90 min after the release of occlusion. Sham operated animals were used as controls. SAO shocked rats had also a marked hypotension and enhanced macrophage and serum levels of TNF-alpha. Furthermore, aortic rings from shocked rats showed a marked hyporeactivity to phenylephrine (PE 1 nM-10 microM) and reduced responsiveness to acetylcholine (ACh 10 nM-10 microM). Endothelium-denuded aortic rings had also a marked hyporeactivity to phenylephrine, which was restored to control values by in vitro administration of NG nitro-L-arginine-methyl ester (L-NAME 10 microM). 3. In vivo administration of cloricromene (2 mg kg-1, i.v.), an inhibitor of TNF-alpha biosynthesis, increased survival, enhanced mean arterial blood pressure and reduced macrophage and serum levels of TNF-alpha. Furthermore, aortic rings from shocked rats treated with cloricromene exhibited a greater contractile response to phenylephrine and improved responsiveness to ACh when compared to aortic rings from vehicle-treated SAO shocked rats. 4. Our results suggest that TNF-alpha alters both endothelial and muscular L-arginine/nitric oxide pathways which in turn produce vascular dysfunction in SAO shock.
Similar articles
- Effects of S-ethylisothiourea, a potent inhibitor of nitric oxide synthase, alone or in combination with a nitric oxide donor in splanchnic artery occlusion shock.
Squadrito F, Altavilla D, Squadrito G, Campo GM, Ioculano M, Canale P, Rossi F, Saitta A, Caputi AP. Squadrito F, et al. Br J Pharmacol. 1996 Sep;119(1):23-8. doi: 10.1111/j.1476-5381.1996.tb15672.x. Br J Pharmacol. 1996. PMID: 8872352 Free PMC article. - Recombinant human erythropoietin inhibits iNOS activity and reverts vascular dysfunction in splanchnic artery occlusion shock.
Squadrito F, Altavilla D, Squadrito G, Campo GM, Arlotta M, Quartarone C, Saitta A, Caputi AP. Squadrito F, et al. Br J Pharmacol. 1999 May;127(2):482-8. doi: 10.1038/sj.bjp.0702521. Br J Pharmacol. 1999. PMID: 10385249 Free PMC article. - Protective effects of cyclosporin-A in splanchnic artery occlusion shock.
Squadrito F, Altavilla D, Squadrito G, Ferlito M, Deodato B, Arlotta M, Minutoli L, Campo GM, Bova A, Quartarone C, Urna G, Sardella A, Saitta A, Caputi AP. Squadrito F, et al. Br J Pharmacol. 2000 May;130(2):339-44. doi: 10.1038/sj.bjp.0703310. Br J Pharmacol. 2000. PMID: 10807671 Free PMC article. - Tacrolimus suppresses tumour necrosis factor-alpha and protects against splanchnic artery occlusion shock.
Squadrito F, Altavilla D, Squadrito G, Ferlito M, Campo GM, Arlotta M, Grimaldi S, Quartarone C, Saitta A, Caputi AP. Squadrito F, et al. Br J Pharmacol. 1999 May;127(2):498-504. doi: 10.1038/sj.bjp.0702528. Br J Pharmacol. 1999. PMID: 10385251 Free PMC article. - Vasogenic shock physiology.
Gkisioti S, Mentzelopoulos SD. Gkisioti S, et al. Open Access Emerg Med. 2011 Jan 6;3:1-6. doi: 10.2147/OAEM.S10388. eCollection 2011. Open Access Emerg Med. 2011. PMID: 27147845 Free PMC article. Review.
Cited by
- Effects of S-ethylisothiourea, a potent inhibitor of nitric oxide synthase, alone or in combination with a nitric oxide donor in splanchnic artery occlusion shock.
Squadrito F, Altavilla D, Squadrito G, Campo GM, Ioculano M, Canale P, Rossi F, Saitta A, Caputi AP. Squadrito F, et al. Br J Pharmacol. 1996 Sep;119(1):23-8. doi: 10.1111/j.1476-5381.1996.tb15672.x. Br J Pharmacol. 1996. PMID: 8872352 Free PMC article. - Recombinant human erythropoietin inhibits iNOS activity and reverts vascular dysfunction in splanchnic artery occlusion shock.
Squadrito F, Altavilla D, Squadrito G, Campo GM, Arlotta M, Quartarone C, Saitta A, Caputi AP. Squadrito F, et al. Br J Pharmacol. 1999 May;127(2):482-8. doi: 10.1038/sj.bjp.0702521. Br J Pharmacol. 1999. PMID: 10385249 Free PMC article. - Cholinergic control of inflammation.
Rosas-Ballina M, Tracey KJ. Rosas-Ballina M, et al. J Intern Med. 2009 Jun;265(6):663-79. doi: 10.1111/j.1365-2796.2009.02098.x. J Intern Med. 2009. PMID: 19493060 Free PMC article. Review. - Protective effects of cyclosporin-A in splanchnic artery occlusion shock.
Squadrito F, Altavilla D, Squadrito G, Ferlito M, Deodato B, Arlotta M, Minutoli L, Campo GM, Bova A, Quartarone C, Urna G, Sardella A, Saitta A, Caputi AP. Squadrito F, et al. Br J Pharmacol. 2000 May;130(2):339-44. doi: 10.1038/sj.bjp.0703310. Br J Pharmacol. 2000. PMID: 10807671 Free PMC article. - Tacrolimus suppresses tumour necrosis factor-alpha and protects against splanchnic artery occlusion shock.
Squadrito F, Altavilla D, Squadrito G, Ferlito M, Campo GM, Arlotta M, Grimaldi S, Quartarone C, Saitta A, Caputi AP. Squadrito F, et al. Br J Pharmacol. 1999 May;127(2):498-504. doi: 10.1038/sj.bjp.0702528. Br J Pharmacol. 1999. PMID: 10385251 Free PMC article.
References
- J Immunol. 1980 Oct;125(4):1671-7 - PubMed
- Am J Physiol. 1994 Apr;266(4 Pt 2):H1512-5 - PubMed
- Nature. 1987 Jun 11-17;327(6122):524-6 - PubMed
- Circ Shock. 1988;24(1):43-53 - PubMed
- Biochem Biophys Res Commun. 1988 Jun 30;153(3):1251-6 - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical